Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Rigel Pharmaceutical Inc.

Start price
Target price
Perf. (%)
€2.83
20.10.21
€5.00
31.12.23
-62.30%
08.05.23

Could be very worthwhile Investment >20% year
buy
Applied Genetic Technologies Corp.

Start price
Target price
Perf. (%)
€2.28
20.10.21
€5.00
31.12.23
-84.94%
08.05.23

Could be very worthwhile Investment >20% year
buy
Chemocentryx Inc.

Start price
Target price
Perf. (%)
€29.94
20.10.21
€35.00
31.12.23
65.15%
05.08.22

Could be very worthwhile Investment >20% year
buy
Omeros Corp.

Start price
Target price
Perf. (%)
€5.21
19.10.21
-
19.10.22
19.09%
05.11.21

Could be worthwhile Investment >10% per year
buy
Forte Biosciences Inc.

Start price
Target price
Perf. (%)
€2.32
18.10.21
-
18.10.22
6.90%
30.10.21

Capable Management
Could be very worthwhile Investment >20% year
Few uniques
buy
Molecular Templates Inc.

Start price
Target price
Perf. (%)
€5.30
18.10.21
-
18.10.22
-15.62%
30.10.21

Risky Investment
buy
Coherus Bioscien.

Start price
Target price
Perf. (%)
€14.60
17.10.21
€20.00
31.12.23
-54.93%
08.05.23

Could be very worthwhile Investment >20% year
buy
Abeona Therapeutics Inc.

Start price
Target price
Perf. (%)
€19.80
17.10.21
€25.00
17.10.22
-15.53%
26.11.21

Could be worthwhile Investment >10% per year
Concert Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€2.44
17.10.21
-
17.10.22
121.23%
28.05.22

Could be worthwhile Investment >10% per year
Durect Corp.

Start price
Target price
Perf. (%)
€1.03
17.10.21
-
17.10.22
-48.06%
18.10.22

Probably not worthwhile Investment
buy
Minerva Neurosciences Inc.

Start price
Target price
Perf. (%)
€9.36
16.10.21
€20.00
16.10.22
47.44%
17.10.22

Could be worthwhile Investment >10% per year
buy
Carisma Therapeutics Inc.

Start price
Target price
Perf. (%)
€16.58
16.10.21
-
16.10.22
22.56%
24.10.21

Could be worthwhile Investment >10% per year
buy
Carisma Therapeutics Inc.

Start price
Target price
Perf. (%)
€1.13
16.10.21
-
16.10.22
-
16.10.21

Could be worthwhile Investment >10% per year
buy
Carisma Therapeutics Inc.

Start price
Target price
Perf. (%)
€1.13
16.10.21
-
16.10.22
-
16.10.21

Could be worthwhile Investment >10% per year
buy
Carisma Therapeutics Inc.

Start price
Target price
Perf. (%)
€1.13
16.10.21
-
16.10.22
-
16.10.21

Could be worthwhile Investment >10% per year
buy
Chemocentryx Inc.

Start price
Target price
Perf. (%)
€30.25
13.10.21
€34.00
30.07.22
-32.13%
14.03.22

Lower EBIT Margin than peer group
Very low/no dividend yield expected
negative Cash Flow expected
Bad rating
buy
Carisma Therapeutics Inc.

Start price
Target price
Perf. (%)
€15.44
12.10.21
-
12.10.22
7.38%
16.10.21

Could be worthwhile Investment >10% per year
buy
Radius Health Inc.

Start price
Target price
Perf. (%)
€12.84
11.10.21
€20.00
31.12.23
-19.42%
08.05.23

Could be very worthwhile Investment >20% year
buy
Avenue Therapeutics Inc.

Start price
Target price
Perf. (%)
€17.10
10.10.21
€15.00
10.10.22
-84.33%
11.10.22

Could be worthwhile Investment >10% per year
Some uniques
buy
Omeros Corp.

Start price
Target price
Perf. (%)
€6.46
04.10.21
-
04.10.22
-19.39%
19.10.21

Could be worthwhile Investment >10% per year
buy
Novavax Inc.

Start price
Target price
Perf. (%)
€148.30
04.10.21
-
04.10.22
2.14%
15.11.21

Could be worthwhile Investment >10% per year
Some uniques
buy
Molecular Templates Inc.

Start price
Target price
Perf. (%)
€5.50
04.10.21
-
04.10.22
-1.36%
17.10.21

Risky Investment
buy
Forte Biosciences Inc.

Start price
Target price
Perf. (%)
€2.60
04.10.21
-
04.10.22
-4.62%
16.10.21

Capable Management
Could be very worthwhile Investment >20% year
Few uniques
buy
Fate Therapeutics Inc.

Start price
Target price
Perf. (%)
€51.56
03.10.21
-
03.10.22
1.55%
17.10.21

Could be very worthwhile Investment >20% year
Omeros Corp.

Start price
Target price
Perf. (%)
€7.20
02.10.21
-
02.10.22
-53.29%
03.10.22

Probably not worthwhile Investment